Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.67 |
| ▸ | ARG2 | P78540 | 4/20 | 0.43 |
| ▸ | ARG1 | P05089 | 3/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | AGER | Q15109 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL28207112 | 1.00 | GSR (0.67) | GSRARG2ARG1ITGB3ITGA2B | |
| Lysine SCHEMBL28860372 | 0.94 | GSR (0.59) | GSRARG2ARG1ITGB3ITGA2B | |
| Lysine SCHEMBL28207652 | 0.87 | GSR (0.50) | GSRARG2ARG1ITGB3ITGA2B | |
| Lysine SCHEMBL28980840 | 0.84 | GSR (0.74) | GSRARG2ARG1RNPEPPOLB | |
| Lysine SCHEMBL28980842 | 0.84 | GSR (0.74) | GSRARG2ARG1RNPEPPOLB | |
| Lysine SCHEMBL29075874 | 0.84 | GSR (0.95) | GSRARG2ARG1RNPEPCPB2 | |
| Norleucine SCHEMBL27512040 | 0.83 | SLC1A2 (0.49) | GSRDPP7AGER | |
| Lysine SCHEMBL28214073 | 0.82 | GSR (0.91) | GSRARG2ARG1RNPEPPOLB | |
| Lysine SCHEMBL3029499 | 0.82 | GSR (0.91) | GSRARG2ARG1RNPEPCPB2 | |
| Lysine SCHEMBL1000151 | 0.82 | GSR (1.00) | GSRARG2ARG1RNPEPKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029733-B2 | Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system | Tulavi Therapeutics, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11446359-B2 | Systems and methods for cardiac plexus neuromodulation | Tulavi Therapeutics, Inc. (US) | 2022-09-20 | — | — | US | disclosed |
| US-11154547-B2 | Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system | Tulavi Therapeutics, Inc. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210205501-A1 | SYSTEMS AND METHODS FOR GEL-BASED NEUROMODULATION | Tulavi Therapeutics, Inc. | 2021-07-08 | — | — | US | disclosed |
| CN-109675020-B | Oral GLP-1 polypeptide nano preparation and preparation method and application thereof | 浙江大学 | 2021-05-04 | — | — | CN | disclosed |
| EP-3764990-A1 | SYSTEMS AND METHODS FOR GEL-BASED NEUROMODULATION | Tulavi Therapeutics, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-112118828-A | Systems and methods for gel-based neuromodulation | 图拉维治疗股份有限公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20200085809-A1 | TREATMENT OF SEPSIS AND RELATED INFLAMMATORY CONDITIONS BY LOCAL NEUROMODULATION OF THE AUTONOMIC NERVOUS SYSTEM | Tulavi Therapeutics, Inc. | 2020-03-19 | — | — | US | disclosed |
| WO-2019178564-A1 | SYSTEMS AND METHODS FOR GEL-BASED NEUROMODULATION | Tulavi Therapeutics, Inc. (US) | 2019-09-19 | — | — | WO | disclosed |
| CN-110035754-A | Pass through the local nerve adjustment for the treatment of septicemia and the related inflammatory patient's condition of autonomic nerves system | 图拉维治疗股份有限公司 | 2019-07-19 | — | — | CN | disclosed |
| EP-3288626-A1 | SYSTEMS AND MEHTODS FOR SYMPATHETIC CARDIOPULMONARY NEUROMODULATION | Reflex Medical Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| WO-2018005848-A1 | TREATMENT OF SEPSIS AND RELATED INFLAMMATORY CONDITIONS BY LOCAL NEUROMODULATION OF THE AUTONOMIC NERVOUS SYSTEM | BRIGHT, CORINNE (US) | 2018-01-04 | — | — | WO | disclosed |
| US-9855317-B2 | Systems and methods for sympathetic cardiopulmonary neuromodulation | Reflex Medical, Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160317621-A1 | SYSTEMS AND METHODS FOR SYMPATHETIC CARDIOPULMONARY NEUROMODULATION | Tulavi Therapeutics, Inc. | 2016-11-03 | — | — | US | disclosed |
| WO-2016176333-A1 | SYSTEMS AND MEHTODS FOR SYMPATHETIC CARDIOPULMONARY NEUROMODULATION | Reflex Medical, Inc. (US) | 2016-11-03 | — | — | WO | disclosed |
| US-7595198-B2 | Photocleavable isotope-coded affinity tags | AMBERGEN, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080032417-A1 | Photocleavable isotope-coded affinity tags | AMBERGEN, INC | 2008-02-07 | — | — | US | disclosed |
| US-7145019-B2 | Photocleavable isotope-coded affinity tags | AMBERGEN, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| WO-2005037210-A2 | PHOTOCLEAVABLE ISOTOPE-CODED AFFINITY TAGS | AMBERGEN, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050085630-A1 | Photocleavable isotope-coded affinity tags | AMBERGEN INC. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085630-A1 | Photocleavable isotope-coded affinity tags | PTMS, DNPEP, ACP1 | GSR 3944/4885ARG2 4651/4885ARG1 4623/4885 |
| US-20080032417-A1 | Photocleavable isotope-coded affinity tags | PTMS, DNPEP, ACP1 | GSR 3944/4885ARG2 4651/4885ARG1 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.